Related Experiment Videos
AIDSVAX results: an answer, or just more questions?
1American Foundation for AIDS Research, New York, NY 10005-3902, USA. rowena.johnston@amfar.org
AIDS Patient Care and Stds
|March 26, 2003
Abstract:
Some time within the next few weeks, VaxGen is expected to announce the results of the Phase III trials of its first vaccine candidate based on a bivalent HIV envelope gp120, AIDSVAX B/B. Interpretation of these results will probably not be straightforward and will likely lead to many more unanswered questions. Following is a description of some of the key issues involved.